{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:32:01Z","timestamp":1761514321744},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.hbpd.2018.12.009","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T06:53:14Z","timestamp":1545979994000},"page":"62-66","source":"Crossref","is-referenced-by-count":2,"title":["KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study"],"prefix":"10.1016","volume":"18","author":[{"given":"Jung Hyun","family":"Jo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huapyong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Seung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon Jae","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Youp","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seungmin","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2018.12.009_sbref0001","series-title":"Topics in the surgery of the biliary tree","article-title":"Chemotherapy of cholangiocarcinoma: Current management and future directions","author":"Jo","year":"2018"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0003","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0004","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nature19483","article-title":"DNA repair: telomere-lengthening mechanism revealed","volume":"539","author":"Roake","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0006","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mrrev.2016.11.002","article-title":"TERT promoter mutations in telomere biology","volume":"771","author":"Heidenreich","year":"2017","journal-title":"Mutat Res"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0007","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1016\/j.vaccine.2017.09.011","article-title":"Telomerase based anticancer immunotherapy and vaccines approaches","volume":"35","author":"Kailashiya","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0008","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10428199309148558","article-title":"Arsenic and Ayurveda","volume":"10","author":"Treleaven","year":"1993","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.6-suppl_2-3","article-title":"History of the development of arsenic derivatives in cancer therapy","volume":"6","author":"Waxman","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0010","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1182\/blood.V94.10.3315.422k16_3315_3324","article-title":"Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients","volume":"94","author":"Niu","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0011","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0012","first-page":"4957","article-title":"Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines","volume":"6","author":"Uslu","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0013","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0959-8049(99)00106-9","article-title":"Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide","volume":"35","author":"Zhang","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0014","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/mol.62.3.529","article-title":"Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines","volume":"62","author":"Ling","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0015","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1158\/1078-0432.CCR-07-4572","article-title":"KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells","volume":"14","author":"Phatak","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0016","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00280-016-3148-x","article-title":"Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors","volume":"78","author":"Edelman","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10637-015-0301-z","article-title":"Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study","volume":"34","author":"Yoon","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0018","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1158\/0008-5472.CAN-07-0551","article-title":"Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells","volume":"67","author":"Ivanov","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0019","first-page":"183","article-title":"KML001 enhances anticancer activity of gemcitabine against pancreatic cancer cells","volume":"35","author":"Yang","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0021","unstructured":"US Department of Health and Human Services, National Cancer Institute. Common terminology criteria for adverse events (CTCAE), Version 4.0. National Institutes of Health\/National Cancer Institute; 2009:1\u2013194."},{"key":"10.1016\/j.hbpd.2018.12.009_bib0022","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hbpd.2018.12.009_bib0023","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3892\/or.2017.5688","article-title":"KML001 and doxercalciferol induce synergistic antileukemic effect in acute lymphoid leukemia cells","volume":"38","author":"Liu","year":"2017","journal-title":"Oncol Rep"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387218302753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387218302753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T05:00:30Z","timestamp":1573621230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499387218302753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1499387218302753"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2018.12.009","relation":{},"ISSN":["1499-3872"],"issn-type":[{"value":"1499-3872","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}